Arnt Schellekens
Arnt Schellekens
Radboudumc, Donders Institute for Brain, Cognition and Behavior
Verified email at radboudumc.nl
Title
Cited by
Cited by
Year
Disruption of reward processing in addiction: an image-based meta-analysis of functional magnetic resonance imaging studies
M Luijten, AF Schellekens, S Kühn, MWJ Machielse, G Sescousse
JAMA psychiatry 74 (4), 387-398, 2017
2042017
Establishing the dopamine dependency of human striatal signals during reward and punishment reversal learning
ME van der Schaaf, MR van Schouwenburg, DEM Geurts, ...
Cerebral Cortex 24 (3), 633-642, 2014
852014
Co-morbid anxiety disorders predict early relapse after inpatient alcohol treatment
AFA Schellekens, CAJ De Jong, JK Buitelaar, RJ Verkes
European Psychiatry 30 (1), 128-136, 2015
802015
Disrupted sensorimotor gating due to mental fatigue: preliminary evidence
D van der Linden, SAA Massar, AFA Schellekens, BA Ellenbroek, ...
International journal of psychophysiology 62 (1), 168-174, 2006
712006
International consensus statement on screening, diagnosis and treatment of substance use disorder patients with comorbid attention deficit/hyperactivity disorder
CL Crunelle, W van den Brink, F Moggi, M Konstenius, J Franck, FR Levin, ...
European addiction research 24 (1), 43-51, 2018
572018
Reduced dopamine receptor sensitivity as an intermediate phenotype in alcohol dependence and the role of the COMT Val158Met and DRD2 Taq1A genotypes
AFA Schellekens, B Franke, B Ellenbroek, A Cools, CAJ de Jong, ...
Archives of general psychiatry 69 (4), 339-348, 2012
562012
Alcohol dependence and anxiety increase error‐related brain activity
AFA Schellekens, ERA De Bruijn, CAA Van Lankveld, W Hulstijn, ...
Addiction 105 (11), 1928-1934, 2010
512010
COMT Val158Met modulates the effect of childhood adverse experiences on the risk of alcohol dependence
AFA Schellekens, B Franke, B Ellenbroek, A Cools, CAJ de Jong, ...
Addiction biology 18 (2), 344-356, 2013
492013
Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study
GA Kalkman, C Kramers, RT van Dongen, W van den Brink, ...
The Lancet Public Health 4 (10), e498-e505, 2019
462019
The role of the habenula in the transition from reward to misery in substance use and mood disorders
A Batalla, JR Homberg, TV Lipina, G Sescousse, M Luijten, SA Ivanova, ...
Neuroscience & Biobehavioral Reviews 80, 276-285, 2017
442017
Effectiveness and organization of addiction medicine training across the globe
AP Ayu, AFA Schellekens, S Iskandar, L Pinxten, CAJ De Jong
European Addiction Research 21 (5), 223-239, 2015
322015
Pharmacological treatment in γ-hydroxybutyrate (GHB) and γ-butyrolactone (GBL) dependence: detoxification and relapse prevention
RM Kamal, MS van Noorden, W Wannet, H Beurmanjer, BAG Dijkstra, ...
CNS drugs 31 (1), 51-64, 2017
302017
Effect of apomorphine on cognitive performance and sensorimotor gating in humans
AFA Schellekens, KP Grootens, C Neef, KLL Movig, JK Buitelaar, ...
Psychopharmacology 207 (4), 559-569, 2010
292010
Psilocybin for treating substance use disorders?
BTH De Veen, AFA Schellekens, MMM Verheij, JR Homberg
Expert review of neurotherapeutics 17 (2), 203-212, 2017
282017
The level of alexithymia in alcohol-dependent patients does not influence outcomes after inpatient treatment
HA de Haan, AFA Schellekens, J van der Palen, RJ Verkes, JK Buitelaar, ...
The American Journal of Drug and Alcohol Abuse 38 (4), 299-304, 2012
272012
Ibogaine and addiction in the animal model, a systematic review and meta-analysis
M Belgers, M Leenaars, JR Homberg, M Ritskes-Hoitinga, ...
Translational psychiatry 6 (5), e826-e826, 2016
262016
Anatomical connection strength predicts dopaminergic drug effects on fronto-striatal function
MR van Schouwenburg, MP Zwiers, ME van der Schaaf, DEM Geurts, ...
Psychopharmacology 227 (3), 521-531, 2013
252013
Improvement of depression and anxiety after discontinuation of long-term efavirenz treatment
K M Mothapo, A Schellekens, R van Crevel, M Keuter, K Grintjes-Huisman, ...
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2015
242015
Rethinking the risk–benefit ratio of efavirenz in HIV-infected children
L Van de Wijer, AFA Schellekens, DM Burger, JR Homberg, Q de Mast, ...
The Lancet Infectious Diseases 16 (5), e76-e81, 2016
202016
Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring
LC Martial, RE Aarnoutse, M Mulder, A Schellekens, RJM Brüggemann, ...
European Neuropsychopharmacology 27 (3), 205-216, 2017
192017
The system can't perform the operation now. Try again later.
Articles 1–20